{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:10:46Z","timestamp":1759590646684,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clineuro.2023.108040","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:26:06Z","timestamp":1699025166000},"page":"108040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Reversal of pre-injury factor-Xa inhibitors with prothrombin complex concentrates in patients following traumatic brain injury"],"prefix":"10.1016","volume":"235","author":[{"given":"Jeffrey F.","family":"Barletta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina R.","family":"Shirah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia J.","family":"Mangram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Sucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Hostert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberli","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Springs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Zach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2023.108040_bib1","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.clineuro.2023.108040_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"14","key":"10.1016\/j.clineuro.2023.108040_bib3","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clineuro.2023.108040_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.clineuro.2023.108040_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.clineuro.2023.108040_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"24","key":"10.1016\/j.clineuro.2023.108040_bib7","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.clineuro.2023.108040_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US Hospitals","volume":"4","author":"Kanjee","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.clineuro.2023.108040_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12028-020-00968-6","article-title":"Efficacy of 4-factor prothrombin complex concentrates in factor Xa Inhibitor-Associated Intracranial Bleeding","volume":"34","author":"Korobey","year":"2021","journal-title":"Neurocrit Care"},{"issue":"4","key":"10.1016\/j.clineuro.2023.108040_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s10072-019-3726-x","article-title":"Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis","volume":"40","author":"Pan","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clineuro.2023.108040_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am. J. Emerg. Med"},{"issue":"2","key":"10.1016\/j.clineuro.2023.108040_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study","volume":"48","author":"Smith","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.clineuro.2023.108040_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12028-022-01521-3","article-title":"Impact of factor Xa inhibitor reversal with prothrombin complex concentrate in patients with traumatic brain injuries","volume":"37","author":"Cooksey","year":"2022","journal-title":"Neurocrit Care"},{"issue":"1","key":"10.1016\/j.clineuro.2023.108040_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TA.0000000000003421","article-title":"Eastern Association for the Surgery of Trauma Multicenter Trial: comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients","volume":"92","author":"Yorkgitis","year":"2022","journal-title":"J. Trauma Acute Care Surg."},{"issue":"9","key":"10.1016\/j.clineuro.2023.108040_bib15","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1161\/01.STR.29.9.1799","article-title":"Comparison of the ABC\/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial","volume":"29","author":"Gebel","year":"1998","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.clineuro.2023.108040_bib16","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/01.STR.27.8.1304","article-title":"The ABCs of measuring intracerebral hemorrhage volumes","volume":"27","author":"Kothari","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.clineuro.2023.108040_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2023.04.015","article-title":"Clinical relevance of preclinical and clinical studies of four-factor prothrombin complex concentrate for treatment of bleeding related to direct oral anticoagulants","author":"Sarode","year":"2023","journal-title":"Ann. Emerg. Med."},{"issue":"11","key":"10.1016\/j.clineuro.2023.108040_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"21","key":"10.1016\/j.clineuro.2023.108040_bib19","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.clineuro.2023.108040_bib20","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit. Care Med."},{"issue":"1","key":"10.1016\/j.clineuro.2023.108040_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rth2.12015","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro","volume":"1","author":"Schultz","year":"2017","journal-title":"Res. Pr. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.clineuro.2023.108040_bib22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","article-title":"A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?","volume":"38","author":"Milling","year":"2020","journal-title":"Am. J. Emerg. Med."},{"issue":"11","key":"10.1016\/j.clineuro.2023.108040_bib23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0885066619840992","article-title":"A low-dose 4F-PCC protocol for DOAC-Associated Intracranial Hemorrhage","volume":"35","author":"Berger","year":"2020","journal-title":"J. Intensive Care Med"},{"issue":"6","key":"10.1016\/j.clineuro.2023.108040_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/phar.2525","article-title":"Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage","volume":"41","author":"Cascone","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clineuro.2023.108040_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2018.11.009","article-title":"Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants","volume":"173","author":"Dager","year":"2019","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.clineuro.2023.108040_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor-associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2021","journal-title":"J. Intensive Care Med"},{"issue":"2","key":"10.1016\/j.clineuro.2023.108040_bib27","article-title":"Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing","volume":"7","author":"Chiasakul","year":"2023","journal-title":"Res. Pr. Thromb. Haemost."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723004560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723004560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:44:30Z","timestamp":1759589070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846723004560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"alternative-id":["S0303846723004560"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.108040","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of pre-injury factor-Xa inhibitors with prothrombin complex concentrates in patients following traumatic brain injury","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.108040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108040"}}